EWM
AST

Endurance Wealth Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Endurance Wealth Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-16
Closed – – 547
2015
Q3 		$0 Hold
16
– – ﹤0.01% 564
2015
Q2 		$0 Buy
+16
New +$153 ﹤0.01% 543

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Endurance Wealth Management's AST Position: Q4 2015 in Review

Endurance Wealth Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2015, closing a stake of 16 shares.

Endurance Wealth Management first reported a position in AST in Q2 2015 and held it in 2 quarters. The position peaked at $0 in Q3 2015. 56 funds tracked by Wall St. Rank hold AST as of Q4 2015.

  • Endurance Wealth Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2015 after selling out during the quarter.
  • Endurance Wealth Management sold 16 Asterias Biotherapeutics Inc. Series A shares in Q4 2015.
  • Endurance Wealth Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 2 quarters.
  • Endurance Wealth Management's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q3 2015.
  • 56 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2015.

Based on Endurance Wealth Management's 13F filing for Q4 2015, filed 27 Jan 2016.